Brief Communication: Comparison of Changes in Metabolic Parameters Following Antiretrovial Therapy With Treatment Regimens Containing Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate Publisher Pubmed



Mirmoezzi H¹ ; Koochak HE² ; Dehghan Manshadi SA² ; Hasannezhad M^{2, 3} ; Seyedalinaghi S³ ; Semnani K¹ ; Abbasian L^{2, 3} ; Ghaderkhani S^{2, 3}
Source: AIDS Research and Therapy Published:2025

Abstract

Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil fumarate (TDF). We retrospectively evaluated changes in weight and glucose regulation among 153 treament-naive patients. Weight-gain was more pronounced after one year of treatment with TAF versus TDF (3.5 kg versus − 1 kg, P-value < 0.001). However, weight-gain was attenuated with longer follow-up, and no increase in glucose dysregulation was noted for TAF treatment. Attribution of increased metabolic risk to treatment with TAF remains questionable. © The Author(s) 2025.